[go: up one dir, main page]

FI20165814A - Interleukin 8 (il-8) as a prognostic and predictive biomarker as well as compositions and vectors for use in oncolytic immunotherapy - Google Patents

Interleukin 8 (il-8) as a prognostic and predictive biomarker as well as compositions and vectors for use in oncolytic immunotherapy

Info

Publication number
FI20165814A
FI20165814A FI20165814A FI20165814A FI20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A FI 20165814 A FI20165814 A FI 20165814A
Authority
FI
Finland
Prior art keywords
interleukin
prognostic
oncolytic
vectors
compositions
Prior art date
Application number
FI20165814A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI20165814A7 (en
Inventor
Kristian Taipale
Akseli Hemminki
Original Assignee
Tilt Biotherapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilt Biotherapeutics Oy filed Critical Tilt Biotherapeutics Oy
Priority to FI20165814A priority Critical patent/FI20165814A7/en
Priority to PCT/FI2017/050742 priority patent/WO2018078220A1/en
Publication of FI20165814A publication Critical patent/FI20165814A/en
Publication of FI20165814A7 publication Critical patent/FI20165814A7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an oncolytic viral vector comprising a nucleic acid sequence encoding an anti-interleukin 8 neutralizing antibody.Further, the present invention relates to use of interleukin 8 as a prognostic and predictive biomarkerin oncolytic immunotherapy. In this respect, the present invention is directed to a method ofanalysing whether a subject suffering from a cancer is responsive or non-responsive to the treatment with an oncolytic viral vectorand to a method of monitoringefficacy of an oncolytic immunotherapy.
FI20165814A 2016-10-27 2016-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy FI20165814A7 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20165814A FI20165814A7 (en) 2016-10-27 2016-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy
PCT/FI2017/050742 WO2018078220A1 (en) 2016-10-27 2017-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20165814A FI20165814A7 (en) 2016-10-27 2016-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy

Publications (2)

Publication Number Publication Date
FI20165814A true FI20165814A (en) 2018-04-28
FI20165814A7 FI20165814A7 (en) 2018-04-28

Family

ID=60569934

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20165814A FI20165814A7 (en) 2016-10-27 2016-10-27 Interleukin 8 (il-8) as a prognostic and predictive biomarker and compositions and vectors for use in oncolytic immunotherapy

Country Status (2)

Country Link
FI (1) FI20165814A7 (en)
WO (1) WO2018078220A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (en) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ Oncolytic adenovirus composition
KR20220163505A (en) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN112292449A (en) 2018-04-09 2021-01-29 萨克生物研究学院 Oncolytic adenovirus compositions with enhanced replication properties
BR112021007724A2 (en) * 2018-11-12 2021-08-10 Aptarion Biotech Ag cxc18 binding nucleic acids
CN111363726A (en) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 Oncolytic virus expressing interferon and application thereof
CA3134957A1 (en) * 2019-03-28 2020-10-01 Mayo Foundation For Medical Education And Research Ifn.beta. as a pharmacodynamic marker in vsv-ifn.beta.-nis oncolytic therapy
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
CN114518451B (en) * 2021-12-22 2025-09-26 厦门福宸百奥生物技术有限公司 Test strips, test cards, kits for detecting neutralizing antibodies to human adenovirus type 5 and preparation methods thereof
WO2025012635A1 (en) * 2023-07-11 2025-01-16 Theolytics Ltd Adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096781A1 (en) * 2001-08-31 2003-05-22 University Of Southern California IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
ATE527278T1 (en) 2002-12-16 2011-10-15 Genmab As HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)
US9345787B2 (en) * 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP2831112A1 (en) * 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
KR101458947B1 (en) 2013-03-05 2014-11-12 국립암센터 Interleukin-8 aptamers and uses thereof
SG10202004535PA (en) 2013-04-18 2020-06-29 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
RU2725799C2 (en) 2015-03-17 2020-07-06 Тилт Байотерапьютикс Ой Oncolytic adenoviruses encoding bispecific antibodies, as well as methods and applications associated therewith

Also Published As

Publication number Publication date
WO2018078220A1 (en) 2018-05-03
FI20165814A7 (en) 2018-04-28

Similar Documents

Publication Publication Date Title
FI20165814A (en) Interleukin 8 (il-8) as a prognostic and predictive biomarker as well as compositions and vectors for use in oncolytic immunotherapy
MX2025005375A (en) Dnase variants
EP3950941A3 (en) Dnase polypeptide variants
HK1244299A1 (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
MX2020005282A (en) Vector for the production of aav particles.
MX2023001119A (en) VARIANTS OF ENZYMES AND POLINUCLEOTIDES THAT CODE THEM.
EA201891001A1 (en) VACCINES ON THE BASIS OF NUCLEIC ACIDS AGAINST WINDSHEAD VIRUS (VZV)
EP3741848A3 (en) Protease variants and polynucleotides encoding same
BR112017009728A2 (en) isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder
EA201792080A1 (en) HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2018008051A (en) Beta-glucanase variants and polynucleotides encoding same.
MX383537B (en) RSV F PROTEIN MUTANTS.
MX2018014152A (en) Compositions and methods of treating huntington's disease.
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
BR112017015567A2 (en) recombinant cytomegalovirus gl protein or complex formation fragment thereof, cytomegalovirus complex, isolated nucleic acid, host cell, and immunogenic composition
MX2019000140A (en) Xylanase variants and polynucleotides encoding same.
PE20190415A1 (en) HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE OF THEM
BR112016025217A2 (en) method and system for producing reduced gluten oat grain mix
AU2017310785A8 (en) Production method for insoluble recombinant protein aggregate
WO2018017747A3 (en) Oncolytic viruses targeting stat3
HK1231555A1 (en) Biomarker and uses thereof
MX2016013849A (en) A PROTEIN SECRETION FACTOR WITH HIGH EFFECTIVENESS SECRETORA AND AN EXPRESSION VECTOR THAT UNDERSTANDS IT.
EP4357453A3 (en) Lipase variants, polynucleotides encoding same and the use thereof
EA201890351A1 (en) RECOMBINANT ORF-VIRAL VECTOR
SG10201807572PA (en) Robust antibody purification

Legal Events

Date Code Title Description
FD Application lapsed